Galantamine for vascular cognitive impairment
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Vascular dementia represents the second most common type of dementia after that caused by Alzheimer's disease. Particularly in older patients, the combination of vascular dementia and Alzheimer's disease is common and is referred to as mixed dementia. The classification of vascular dementia broadly follows three clinico-pathological processes: multi-infarct dementia, single strategic infarct dementia and subcortical dementia. Not all patients fulfil strict criteria for dementia and may be significantly cognitively impaired without memory loss and the term vascular cognitive impairment is more useful. Currently, no established standard treatment for vascular cognitive impairment exists. Reductions in acetylcholine and acetyltransferase activity are common to both Alzheimer's disease and vascular cognitive impairment raising the possibility that cholinesterase inhibitors such as galantamine may be beneficial for the latter. OBJECTIVES: To assess the efficacy of galantamine in the treatment of people with vascular cognitive impairment or vascular dementia or mixed dementia. SEARCH METHODS: The trials were identified from a search of ALOIS: the Cochrane Dementia and Cognitive Improvement Group's Specialized Register on 12 January 2013. The register contains information on trials identified from frequent searches of a number of major healthcare and medical databases (MEDLINE, EMBASE, PsycINFO, CINAHL and LILACS) as well as from a number of international and national trial registries and grey literature sources. The terms used were: galantamine, galanthamine, Reminyl, Razadyne, Nival in. SELECTION CRITERIA: All unconfounded randomised double-blind trials comparing galantamine with placebo were eligible for inclusion. DATA COLLECTION AND ANALYSIS: Two review authors independently extracted the data from included studies. MAIN RESULTS: Two trials, 1378 participants, employing randomised, double-blind, parallel-group methodology were included. Both trials were of six months duration and were testing a galantamine dose of 16-24 mg/day in two divided doses. Both trials had an overall low risk of bias.The GAL-INT-6 trial included 592 patients with vascular dementia diagnosed according to recognised criteria and patients with Alzheimer's disease and coincidental radiographic findings of cerebrovascular disease. Limited outcome data were reported for the subgroup data with vascular dementia. In the whole trial population, statistically significant treatment effects in favour of galantamine compared with placebo in cognition (ADAS-cog,mean difference (MD) -2.29, 95%confidence interval (CI) -3.46 to -1.12, P = 0.0001), activities of daily living (DAD, MD 4.10, 95% CI 1.25 to 6.95, P = 0.005) and behaviour (NPI, MD -2.06, 95% CI -4.09 to -0.03,P = 0.05 ) were noted. Significantly higher numbers of patients dropped out, (102/396 galantamine, 33/196 placebo odds ratio (OR)1.71, 95% CL 1.11 to 2.65, P = 0.02) and withdrew due to an adverse event from the group treated with galantamine compared with the placebo group (79/396 galantamine, 16/196 placebo, OR 2.80, 95% CI 1.59 to 4.95, P =0.0004).Data were also included from a second larger trial (GAL-INT-26) involving 788 patients with vascular dementia diagnosed using standard criteria. Statistically significant benefits favouring galantamine over placebo in assessments of cognition (ADAS-cog, MD -1.50, 95% CI -2.39 to -0.61, P = 0.0009), and favouring placebo compared with galantamine for behaviour (NPI, MD 1.80, 95% CI0.29 to 3.31, P = 0.02) are recorded. Significantly higher numbers of patients dropped out from the group treated with galantamine compared with the placebo group (50/396 galantamine, 25/390 placebo OR 2.11, 95% CL 1.28 to 3.49, P = 0.004). AUTHORS' CONCLUSIONS: Limited data were available when considering the impact of galantamine on vascular dementia or vascular cognitive impairment. The data available suggest some advantage over placebo in the areas of cognition and global clinical state. In both included trials galantamine produced higher rates of gastrointestinal side-effects. More studies are needed before firm conclusions can be drawn.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., & Gornbein, J. (1994) · Neurology · doi:10.1212/wnl.44.12.2308 · Cited by 7,568
Román, G. C., Tatemichi, T. K., Erkinjuntti, T., Cummings, J. L., Masdeu, J. C., Garcia, J. H., Amaducci, L., Orgogozo, J.-M., Brun, A., Hofman, A., et al. (1993) · Neurology · doi:10.1212/wnl.43.2.250 · Cited by 4,921
Frontal-subcortical circuits and human behavior
Cummings, J. L. (1993) · Archives of Neurology · doi:10.1001/archneur.1993.00540080076020 · Cited by 2,262
(2001) · The Lancet · doi:10.1016/s0140-6736(00)03589-3 · Cited by 1,338
Chui, H. C., Victoroff, J. I., Margolin, D., Jagust, W., Shankle, R., & Katzman, R. (1992) · Neurology · doi:10.1212/wnl.42.3.473 · Cited by 1,201
O'Brien, J. T., Erkinjuntti, T., Reisberg, B., Roman, G., Sawada, T., Pantoni, L., Bowler, J. V., Ballard, C., DeCarli, C., Gorelick, P. B., et al. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00305-3 · Cited by 1,139
Erkinjuntti, T., Kurz, A., Gauthier, S., Bullock, R., Lilienfeld, S., & Damaraju, C. V. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08267-3 · Cited by 752
Galantamine treatment of vascular dementia: A randomized trial
Auchus, A. P., Brashear, H. R., Salloway, S., Korczyn, A. D., De Deyn, P. P., & Gassmann-Mayer, C. (2007) · Neurology · doi:10.1212/01.wnl.0000266625.31615.f6 · Cited by 189
Rivastigmine in subcortical vascular dementia
Moretti, R., Torre, P., Antonello, R. M., Cazzato, G., & Bava, A. (2002) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(02)00280-0 · Cited by 107
Research works printed but not linked: 29
- Bullock, 2004, Management of patients with Alzheimer's disease plus cerebrovascular disease: 12-month treatment with galantamine, Dementia and Geriatric Cognitive Disorders, 17, 29, 10.1159/000074140 · DOI · Paper page
- Bullock, 2001, Galantamine shows promising results in Alzheimer's disease with cerebrovascular components and probable vascular dementia (preliminary results), Journal of Neuroscience, 187, S59
- Burke W Lilienfeld S Galantamine improves behaviour and relieves caregiver distress in Alzheimer's disease (AD), vascular dementia and AD with cerebrovascular disease Proceedings of the 8th International Conference on Alzheimer's Disease and Related Disorders; 2002 July 20-25, Stockholm, Sweden 2002:Abstract No 428 2002
- Erkinjuntti, 2002, Broad therapeutic benefits in patients with probable vascular dementia or Alzheimer's disease with cerebrovascular disease after treatment with galantamine, European Journal of Neurology, 9, 545, 10.1046/j.1468-1331.2002.04455.x · DOI
- Erkinjuntti, 2008, Galantamine treatment in Alzheimer's disease with cerebrovascular disease: Responder analyses from a randomized, controlled trial (GAL-INT-6), Journal of Psychopharmacology, 22, 761, 10.1177/0269881107083028 · DOI
- Erkinjuntti, 2003, An open-label extension trial of galantamine in patients with probable vascular dementia and mixed dementia, Clinical Therapeutics, 25, 1765, 10.1016/S0149-2918(03)80168-6 · DOI
- Erkinjuntti T Lilienfed S Cognitive benefits with 12 months of galantamine treatment in patients with Alzheimer's disease and concomitant cerebrovascular disease (mixed dementia) Proceedings of the 8th International Conference on Alzheimer's Disease and Related Disorders; 2002 July 20-25, Stockholm, Sweden 2002:Abstract No 446 2002
- Erkinjuntti T Lilienfeld S Damaraju CV Long-term treatment with galantamine is effective in slowing cognitive decline in patients with probable vascular dementia Proceedings of the 7th International Geneva/Springfield Symposium on Advances in Alzheimer therapy, Apr 3-6, Geneva 2002:181 2002
- Kertesz, 2002, Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomized trial, Current Neurology & Neuroscience Reports, 2, 503, 10.1007/s11910-002-0036-z · DOI
- Kurz, 2002, Non-cognitive benefits of galantamine (Reminyl(R)) treatment in vascular dementia, Acta Neurologica Scandinavica, 106, 19, 10.1034/j.1600-0404.106.s178.5.x · DOI
- Kurz A Lilienfeld S Damaraju CV Galantamine is safe and effective for the long-term treatment of cognitive decline in patients with Alzheimer disease with cerebrovascular components or probable vascular dementia Proceedings of the 7th International Geneva/Springfield Symposium on Advances in Alzheimer therapy, Apr 3-6, Geneva 2002:206 2002
- Kurz, 2003, Long-term safety and cognitive effects of galantamine in the treatment of probable vascular dementia or Alzheimer's disease with cerebrovascular disease, European Journal of Neurology the official journal of the European Federation of Neurological Societies, 10, 633, 10.1046/j.1468-1331.2003.00677.x · DOI · Paper page
- Small, 2003, Galantamine in the treatment of cognitive decline in patients with vascular dementia or Alzheimer's disease with cerebrovascular disease, CNS drugs, 17, 905, 10.2165/00023210-200317120-00004 · DOI
- Small, 2003, Galantamine in the treatment of cognitive decline in patients with vascular dementia or Alzheimer's disease with cerebrovascular disease, CNS Drugs, 17, 905, 10.2165/00023210-200317120-00004 · DOI
- Galasko, 1997, An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study, Alzheimer's Disease and Associated Disorders, 11 Suppl 2, S33, 10.1097/00002093-199700112-00005 · DOI · Paper page
- Gelinas, 1999, Development of a functional measure for persons with Alzheimer's disease: the Disability Assessment for Dementia, American Journal of Occupational Therapy, 53, 471, 10.5014/ajot.53.5.471 · DOI · Paper page
- Knopman, 1994, The Clinician Interview Based Impression (CIBI): a clinician's global change rating scale in Alzheimer's disease, Neurology, 44, 2315, 10.1212/WNL.44.12.2315 · DOI · Paper page
- Lilienfeld, 2002, Galantamine: a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease, CNS Drug Reviews, 8, 159, 10.1111/j.1527-3458.2002.tb00221.x · DOI · Paper page
- Malouf, 2004, Donepezil for vascular cognitive impairment, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD004395.pub2 · DOI · Paper page
- McKhann, 1984, Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Sciences Task Force on Alzheimer's disease, Neurology, 34, 939, 10.1212/WNL.34.7.939 · DOI · Paper page
- O'Brien, 2000, The association between white matter lesions on magnetic resonance imaging and noncognitive symptoms, Annals of the New York Academy of Sciences, 903, 482, 10.1111/j.1749-6632.2000.tb06403.x · DOI · Paper page
- Perry, 1997, Some developments in brain ageing and dementia, British Journal of Biomedical Science, 54, 201
- Perry, 2005, Absence of cholinergic deficits in "pure" vascular dementia, Neurology, 64, 132, 10.1212/01.WNL.0000148591.63727.80 · DOI · Paper page
- Pohjasvaara, 2003, Clinical features of MRI-defined subcortical vascular disease, Alzheimer's Disease and Associated Disorders, 17, 236, 10.1097/00002093-200310000-00007 · DOI
- Rosen, 1984, A new rating scale for Alzheimer's disease, American Journal of Psychiatry, 141, 1356, 10.1176/ajp.141.11.1356 · DOI · Paper page
- Royall, 1992, Bedside assessment of executive cognitive impairment: the executive interview, Journal of the American Geriatrics Society, 40, 1221, 10.1111/j.1532-5415.1992.tb03646.x · DOI · Paper page
- Toghi, 1996, Cerebrospinal fluid acetylcholine and choline in vascular dementia of Binswanger and multiple small infarcts types as compared with Alzheimer-type dementia, Journal of Neural Transmission, 103, 1211, 10.1007/BF01271206 · DOI · Paper page
- World Health Organization, 1992, International classification of diseases, 10th revision
- Craig, 2006, Galantamine for vascular cognitive impairment, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD004746.pub2
Cited by
Gorelick, P. B., Scuteri, A., Black, S. E., DeCarli, C., Greenberg, S. M., Iadecola, C., Launer, L. J., Laurent, S., Lopez, O. L., Nyenhuis, D., et al. (2011) · Stroke · doi:10.1161/str.0b013e3182299496 · Cited by 3,811
Post-stroke cognitive impairment: epidemiology, mechanisms and management.
(2014) · PubMed Central · doi:10.3978/j.issn.2305-5839.2014.08.05 · Cited by 680
Waldemar, G., Dubois, B., Emre, M., Georges, J., McKeith, I. G., Rossor, M., Scheltens, P., Tariska, P., & Winblad, B. (2007) · European Journal of Neurology · doi:10.1111/j.1468-1331.2006.01605.x · Cited by 617
Kavirajan, H., & Schneider, L. S. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70195-3 · Cited by 497
Hogan, D. B., Bailey, P., Black, S., Carswell, A., Chertkow, H., Clarke, B., Cohen, C., Fisk, J. D., Forbes, D., Man-Son-Hing, M., et al. (2008) · Canadian Medical Association Journal · doi:10.1503/cmaj.081103 · Cited by 167
“The response to galantamine seen in patients with combined Alzheimer and cerebrovascular disease might be due to the drug’s effect on the Alzheimer component.(35) At the time of the consensus conference it was felt that donepezil could be considered a treatment option for vascular Review”
Background
Metadata
- Authors
- Birks, J., & Craig, D.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2006-01-25
- Volume
- 2013
- Issue
- 4
- Pages
- CD004746-CD004746
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W1864818198
- Cited by
- 136
- References
- 10
- FWCI
- 6.13
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Galantamine for vascular cognitive impairment. https://app.cochat.ai/papers/10.1002/14651858.cd004746.pub2
- The paper
- Birks, J., & Craig, D. (2006). Galantamine for vascular cognitive impairment. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd004746.pub2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.